POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PD 0348292, AN ORAL, DIRECT FACTOR XA INHIBITOR, IN HEALTHY SUBJECTS.

被引：0
|
作者：
Xuan, D. [1 ]
Boyd, R. [1 ]
DiCarlo, L. [1 ]
机构：
[1] Pfizer Inc, New London, CT USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S54 / S55
页数：2
相关论文
共 50 条
  • [1] Safety, Pharmacokinetics, and Pharmacodynamics of PD 0348292, an Oral, Direct Factor Xa Inhibitor, After Single and Multiple Dosings in Healthy Subjects
    Xuan, Dawei
    McBride, Scott
    Wastall, Philip
    Porcari, Anthony
    DiCarlo, Lorenzo
    Boyd, Rebecca A.
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (01): : 13 - 26
  • [2] Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor in healthy subjects
    Mueck, W.
    Becka, M.
    Kubitza, D.
    Voith, B.
    Zuehlsdorf, M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (06) : 335 - 344
  • [3] EFFECT OF FAMOTIDINE ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Uprett, Vijay V.
    Song, Yan
    Wang, Jessie
    Farmer, Mathew
    Pursley, Janica M.
    Li, Tong
    Frost, Charles E.
    LaCreta, Frank P.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1117 - 1117
  • [4] EFFECT OF BODY WEIGHT ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Upreti, Vijay V.
    Wang, Jessie
    Barrett, Yuchen
    Boyd, Rebecca
    Bui, Anh
    Li, Tong
    LaCreta, Frank P.
    Frost, Charles E.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1060 - 1060
  • [5] POPULATION PHARMACOKINETICS OF PD 0348292, AN ORAL, DIRECT FACTOR XA INHIBITOR, IN TOTAL KNEE REPLACEMENT SURGERY PATIENTS.
    Xuan, D.
    Boyd, R.
    DiCarlo, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S54 - S54
  • [6] Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor
    Kreutz, Reinhold
    [J]. CURRENT CLINICAL PHARMACOLOGY, 2014, 9 (01): : 75 - 83
  • [7] Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
    Frost, Charles
    Nepal, Sunil
    Wang, Jessie
    Schuster, Alan
    Byon, Wonkyung
    Boyd, Rebecca A.
    Yu, Zhigang
    Shenker, Andrew
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    LaCreta, Frank
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (05) : 776 - 786
  • [8] Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
    Frost, Charles
    Wang, Jessie
    Nepal, Sunil
    Schuster, Alan
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    Reeves, Richard A.
    LaCreta, Frank
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 476 - 487
  • [9] Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
    Zhao, Xia
    Sun, Peihong
    Zhou, Ying
    Liu, Yuwang
    Zhang, Huilin
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Zhang, Hong
    Cui, Yimin
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 77 - 88
  • [10] Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects
    Kadokura, Takeshi
    Oikawa, Keishi
    Miyata, Koji
    Murase, Toshinobu
    Nakamura, Mashio
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 328 - 335
12345